Immunological Map for Therapy Prediction - Immunohistochemistry (IHC) Interpretation and Consultation (7 Markers)

A specialized immuno-oncology consultative package is based on the integrated analysis of seven immunohistochemical (IHC) markers designed to assess the tumor immune microenvironment (TIME) and predict the response to immune checkpoint inhibitors (ICIs). The package typically includes: immune activation markers (such as CD8 and Granzyme B), immune fatigue markers (PD-L1, PD-1, and LAG-3), suppressor cell markers (FoxP3 for regulatory T cells or CD163 for M2 macrophages), and a T cell proliferation marker (such as Ki-67 on CD8+ cells). Interpretation is performed by a pathologist specializing in patho-immunology to determine the tumor's immunophenotype (hot, cold, isolated, or drained).